

Adam D Durbin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5016013/publications.pdf>

Version: 2024-02-01

37
papers

2,330
citations

394421

19
h-index

361022

35
g-index

40
all docs

40
docs citations

40
times ranked

4675
citing authors

#	ARTICLE	IF	CITATIONS
1	An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. <i>Science</i> , 2014, 346, 1373-1377.	12.6	665
2	Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. <i>Nature</i> , 2015, 528, 418-421.	27.8	263
3	Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. <i>Nature Genetics</i> , 2018, 50, 1240-1246.	21.4	199
4	<i>MYC</i> Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification. <i>Cancer Discovery</i> , 2018, 8, 320-335.	9.4	172
5	Recurrent Focal Copy-Number Changes and Loss of Heterozygosity Implicate Two Noncoding RNAs and One Tumor Suppressor Gene at Chromosome 3q13.31 in Osteosarcoma. <i>Cancer Research</i> , 2010, 70, 160-171.	0.9	152
6	Advances towards understanding heart valve response to injury. <i>Cardiovascular Pathology</i> , 2002, 11, 69-77.	1.6	107
7	A first-generation pediatric cancer dependency map. <i>Nature Genetics</i> , 2021, 53, 529-538.	21.4	76
8	EP300 Selectively Controls the Enhancer Landscape of <i>MYCN</i> -Amplified Neuroblastoma. <i>Cancer Discovery</i> , 2022, 12, 730-751.	9.4	64
9	ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry. <i>Nature Communications</i> , 2019, 10, 5622.	12.8	56
10	The NOTCH1/SNAI1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. <i>Cell Reports</i> , 2017, 19, 2304-2318.	6.4	53
11	ARID1A loss in neuroblastoma promotes the adrenergic-to-mesenchymal transition by regulating enhancer-mediated gene expression. <i>Science Advances</i> , 2020, 6, eaaz3440.	10.3	47
12	Using Chemical Epigenetics to Target Cancer. <i>Molecular Cell</i> , 2020, 78, 1086-1095.	9.7	40
13	JNK1 determines the oncogenic or tumor-suppressive activity of the integrin-linked kinase in human rhabdomyosarcoma. <i>Journal of Clinical Investigation</i> , 2009, 119, 1558-70.	8.2	36
14	Expression of Insulin-Like Growth Factor Pathway Proteins in Rhabdomyosarcoma: IGF-2 Expression is Associated with Translocation-Negative Tumors. <i>Pediatric and Developmental Pathology</i> , 2009, 12, 127-135.	1.0	34
15	LIN28B regulates transcription and potentiates MYCN-induced neuroblastoma through binding to ZNF143 at target gene promoters. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 16516-16526.	7.1	31
16	The CXCR4-SDF1 β axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma. <i>Clinical and Experimental Metastasis</i> , 2008, 25, 1-10.	3.3	28
17	Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. <i>Cell Reports</i> , 2020, 33, 108493.	6.4	28
18	Retinoic acid rewires the adrenergic core regulatory circuitry of childhood neuroblastoma. <i>Science Advances</i> , 2021, 7, eabe0834.	10.3	22

#	ARTICLE	IF	CITATIONS
19	The Estrogen Receptor Pathway in Rhabdomyosarcoma: A Role for Estrogen Receptor- β in Proliferation and Response to the Antiestrogen 4-OH-Tamoxifen. <i>Cancer Research</i> , 2008, 68, 3476-3485.	0.9	21
20	Nitric oxide promotes in vitro interstitial cell heart valve repair. <i>Cardiovascular Pathology</i> , 2005, 14, 12-18.	1.6	20
21	Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2021, 2, 370-387.	5.0	19
22	Malignant Peripheral Nerve Sheath Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2016, 916, 495-530.	1.6	18
23	Oncogenic ILK, tumor suppression and all that JNK. <i>Cell Cycle</i> , 2009, 8, 4060-4066.	2.6	17
24	Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors. <i>Oncogene</i> , 2019, 38, 6585-6598.	5.9	16
25	Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitors. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	12
26	MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation. <i>Cancers</i> , 2021, 13, 4783.	3.7	12
27	SIX1 reprograms myogenic transcription factors to maintain the rhabdomyosarcoma undifferentiated state. <i>Cell Reports</i> , 2022, 38, 110323.	6.4	12
28	Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights. <i>Cell Reports Medicine</i> , 2022, 3, 100632.	6.5	12
29	Diffusion-Weighted Imaging Changes in a Child With Posterior Ischemic Optic Neuropathy. <i>Pediatric Neurology</i> , 2018, 84, 49-52.	2.1	6
30	Vitamin B12 Deficiency Presenting with Neurological Dysfunction in an Adolescent. <i>Pediatric Neurology</i> , 2016, 62, 66-70.	2.1	5
31	The oncogenic and growth-suppressive functions of the integrin-linked kinase are distinguished by JNK1 expression in human cancer cells. <i>Cell Cycle</i> , 2010, 9, 1951-1959.	2.6	4
32	Targeting ganglioneuromas with mTOR inhibitors. <i>Molecular and Cellular Oncology</i> , 2021, 8, 1856621.	0.7	2
33	A Resident-Led Virtual Journal Club to Educate Pediatric Residents About Coronavirus Disease 2019. <i>Academic Pediatrics</i> , 2021, 21, 759-761.	2.0	1
34	Abstract 2007: Transcriptional regulatory program controlled by the oncogenic transcription factor LMO1 in neuroblastoma. <i>Cancer Research</i> , 2016, 76, 2007-2007.	0.9	1
35	Abstract 3400: Recurrent focal copy-number changes and loss-of-heterozygosity implicate two non-coding RNAs and one tumor-suppressor gene at chromosome 3q13.31 in osteosarcoma. , 2010, , .		1
36	Abstract 2481: Time-resolved transcriptome analysis of murine TH-MYCN driven neuroblastoma identifies MEIS2 as early initiating factor and novel core gene regulatory circuitry constituent. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
37	OPPOSING FUNCTIONS FOR A PROTEIN KINASE: A JNK1 DEPENDENT SWITCH DETERMINES THE ONCOGENIC OR TUMOR SUPPRESSIVE ACTIVITY OF ILK IN RHABDOMYOSARCOMA. <i>Clinical and Investigative Medicine</i> , 2008, 31, 9.	0.6	0